Comparative Pharmacology
Head-to-head clinical analysis: ALA SCALP versus APHTHASOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALA SCALP versus APHTHASOL.
ALA-SCALP vs APHTHASOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ALA-SCALP (aminolevulinic acid) is a photosensitizer precursor that is converted intracellularly to protoporphyrin IX (PpIX), which accumulates in cells with increased heme synthesis, such as rapidly dividing cells. Upon exposure to blue light (BLU-U®), PpIX produces reactive oxygen species, leading to cellular damage and apoptosis of targeted cells.
Aphthasol (amlexanox) is an anti-inflammatory agent that inhibits the formation and release of inflammatory mediators such as histamine and leukotrienes from mast cells, neutrophils, and other inflammatory cells. It also inhibits the activation of eosinophils and neutrophils, and reduces cytokine production, thereby suppressing the immune response involved in aphthous ulcer formation.
Topical application of a 5% solution to the scalp twice daily.
Adults: 5 mg orally three times daily for 5 days.
None Documented
None Documented
Not applicable; topical ALA-SCALP is not significantly absorbed systemically. After systemic absorption from photodynamic therapy, terminal half-life is approximately 1 hour due to rapid metabolism.
Terminal elimination half-life is 1.5 to 2.5 hours. This short half-life supports multiple daily dosing for local therapeutic effect with minimal systemic accumulation.
Primarily renal elimination of metabolites; <1% excreted unchanged in urine. Biliary/fecal excretion is negligible.
Renal excretion of unchanged drug and metabolites accounts for approximately 50-60% of the administered dose, with the remainder eliminated via biliary/fecal routes as metabolites and unchanged drug. Biliary excretion constitutes about 20-30%.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid